Vaccines, Blood & Biologics

Development of strategies to improve cell therapy product characterization

Steven R. Bauer, Ph.D. Headshot

Development of strategies to improve cell therapy product characterization

Steven R. Bauer, Ph.D.

Office of Tissues and Advanced Therapies
Division of Cellular and Gene Therapies
Cellular and Tissue Therapy Branch

Steven.Bauer@fda.hhs.gov


Bauer-Biosketch-Early Morphology Predicts Biological Response

Biosketch

Steven R. Bauer, Ph.D., is the Chief of the Cellular and Tissue Therapy Branch (CTTB), Division of Cellular and Gene Therapies (DCGT) in the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA). As the chief of CTTB, Dr. Bauer supervises CBER scientific staff engaged in review of cell-based biological therapies, policy development in emerging areas of cellular therapies, and research relevant to their use in clinical trials. He is currently studying mesenchymal stem cell biology and stromal cell-hematopoietic cell interactions that influence development of lymphocytes. Dr. Bauer received his Ph.D. in Biochemistry from the University of Maryland in 1986. From 1986 through 1991, Dr. Bauer was a scientific member of the Basel Institute for Immunology in Basel, Switzerland. In 1991, Dr. Bauer joined CBER’s Division of Cellular and Gene Therapies.


General Overview

Cell-based therapies show great promise for repairing, replacing, restoring, or regenerating damaged cells, tissues and organs. Researchers are working to develop cell-based treatments that are both effective and safe.

Many cell-based therapies use stem cells (SC) that are removed from the body and put into cultures in the laboratory, where they multiply before being infused into the patient. SCs are immature cells that replicate themselves and have the ability to give rise to a variety of different types of cells.

For cell therapies based on embryonic stem cells, stem cells are first stimulated to mature before they are given to a patient. However, embryonic stem cells can cause tumors, so products based on them should not have undifferentiated embryonic stem cells contaminating the product given to patients. Also, more mature cells may be better suited for replacing specific types of damaged or lost cells, or for repairing damaged tissue.

A major challenge posed by SC therapy is the need to ensure their efficacy and safety. Cells manufactured in large quantities outside their natural environment in the human body can become ineffective or dangerous and produce significant adverse effects, such as tumors, severe immune reactions, or growth of unwanted tissue. In response to this challenge, FDA scientists are developing laboratory techniques that will enable the agency to carefully evaluate and characterize these products in order to reliably predict whether they will be safe and effective.

Our laboratories use cell cultures and animal models to develop such techniques and to study the biochemical signals that govern cell behavior during manufacturing and after administration to patients. We are currently using mesenchymal stromal cells, or MSCs, (widely called mesenchymal stem cells) to improve strategies for predicting characteristics of stem-cell based cell products.

These studies will help us develop tests that are practical and applicable to specific manufacturing steps.


Scientific Overview

Our objective is to identify the molecules that exert critical influence on the growth and differentiation of SCs. Such molecules can be used in tests that evaluate and characterize cells during the manufacturing process and as lot-release measurements for cell-therapy products. Lot release tests are done to ensure the safety and quality of products before they are shipped from manufacturing facilities.

Our strategy includes developing tests that reliably quantify the amount of various biological activities that are present in different MSC populations. Using such assays, we found that several biological activities decrease the longer MSCs are cultured, and that MSCs derived from different donors vary in the amount of these activities. The activities that follow this pattern include the ability to generate fat (adipocytes), to mineralize (an indicator of bone formation), and to mediate immunosuppression.

The next step is to identify informative molecular markers--molecules whose presence reflects specific states of activity, disease, response to drugs, potency, and other characteristics of cells and tissues. Once we can quantify specific activities in MSC preparations, we can look for molecular signatures that correlate with the quantities we measure in our biological assays. In order to discover such markers on MSCs, we use a variety of technologies. Our major tools are microarrays (devices that enable the study of the state of activity of tens of thousands of genes at a time), RT-PCR (a technique for rapidly making thousands of copies of pieces of DNA), and flow cytometry (a technique for automatically identifying, counting and examining very large numbers of cells).

Another strategy is to study specific molecules that have been shown to influence development or biological activities of MSCs. We are now studying the role of a protein called DLK in a strain of mouse that is genetically deficient in this protein. In these mice we found that DLK influences the generation of MSCs and their ability to turn into bone and fat. Our studies have also shown that DLK influences development of B-lymphocytes, the immune system cells that produce antibodies.

While using MSCs from this mouse strain to study how DLK helps to control the development of bone and fat tissues, we discovered previously unknown roles that DLK plays in these processes. We've gained important new insights into interactions between MSC cells and the cells that give rise to B lymphocytes.

These studies will likely help us to develop improved methods for testing MSC products to ensure they will be safe and effective when used as therapies. This new knowledge will also help us to discover more informative markers for testing MSC-based products.


Important Links


Publications

  1. Proc Natl Acad Sci U S A 2017 Mar 28;114(13):E2598-607
    Morphological features of IFN-gamma-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity.
    Klinker MW, Marklein RA, Lo Surdo JL, Wei CH, Bauer SR
  2. Nat Genet 2016 Dec;48(12):1473-80
    Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction.
    Cleaton MA, Dent CL, Howard M, Corish JA, Gutteridge I, Sovio U, Gaccioli F, Takahashi N, Bauer SR, Charnock-Jones DS, Powell TL, Smith GC, Ferguson-Smith AC, Charalambous M
  3. Oncotarget 2016 Sep 20;7(38):60986-99
    Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.
    Underbayev C, Kasar S, Ruezinsky W, Degheidy H, Schneider JS, Marti G, Bauer SR, Fraidenraich D, Lightfoote MM, Parashar V, Raveche E, Batish M
  4. Stem Cells Dev 2016 Jun 1;25(11):861-73
    Identification of predictive gene markers for multipotent stromal cell proliferation.
    Bellayr IH, Marklein RA, Lo Surdo JL, Bauer SR, Puri RK
  5. Stem Cells 2016 Apr;34(4):935-47
    High content imaging of early morphological signatures predicts long term mineralization capacity of human mesenchymal stem cells upon osteogenic induction.
    Marklein RA, Lo Surdo JL, Bellayr IH, Godil SA, Puri RK, Bauer SR
  6. PLoS One 2016 Mar 9;11(3):e0149331
    Alterations in the mir-15a/16-1 loci impairs its processing and augments B-1 expansion in de novo mouse model of chronic lymphocytic leukemia (CLL).
    Kasar S, Underbayev C, Hassan M, Ilev I, Degheidy H, Bauer S, Marti G, Lutz C, Raveche E, Batish M
  7. Cytometry B Clin Cytom 2016 Mar;90(2):159-67
    Consistent, multi-instrument single tube quantification of CD20 in antibody bound per cell based on CD4 reference.
    Degheidy H, Abbasi F, Mostowski H, Gaigalas AK, Marti G, Bauer S, Wang L
  8. Cytotherapy 2016 Mar;18(3):336-43
    Chromosomal stability of mesenchymal stromal cells during in vitro culture.
    Stultz BG, McGinnis K, Thompson EE, Lo Surdo JL, Bauer SR, Hursh DA
  9. Curr Protoc Cytom 2016 Jan 6;75:1.29.1-1.29.14
    Quantitative flow cytometry measurements in antibodies bound per cell based on a CD4 reference.
    Wang L, Degheidy H, Abbasi F, Mostowski H, Marti G, Bauer S, Hoffman RA, Gaigalas AK
  10. Data Brief 2015 Nov 1;5:864-70
    The proteomic dataset for bone marrow derived human mesenchymal stromal cells: effect of in vitro passaging.
    Mindaye ST, Lo Surdo J, Bauer SR, Alterman MA
  11. Stem Cell Res 2015 Oct 30;15(3):655-64
    System-wide survey of proteomic responses of human bone marrow stromal cells (hBMSCs) to in vitro cultivation.
    Mindaye ST, Surdo JL, Bauer SR, Alterman MA
  12. Stem Cells 2015 Jul;33(7):2169-81
    Chromatin changes at the PPAR-γ2 promoter during bone marrow-derived multipotent stromal cell culture correlate with loss of gene activation potential.
    Lynch PJ, Thompson EE, McGinnis K, Rovira Gonzalez YI, Lo Surdo J, Bauer SR, Hursh DA
  13. BMC Biology 2014 Dec 31;12:771
    Antagonistic roles in fetal development and adult physiology for the oppositely imprinted Grb10 and Dlk1 genes.
    Madon-Simon M, Cowley M, Garfield AS, Moorwood K, Bauer SR, Ward A
  14. Thromb Haemost 2014 Sep 29;112(4):770-80
    Isolation of a circulating CD45-, CD34dim cell population and validation of their endothelial phenotype.
    Tropea MM, Harper BJ, Graninger GM, Phillips TM, Ferreyra G, Mostowski HS, Danner RL, Suffredini AF, Solomon MA
  15. Stem Cell Res Ther 2014 Apr 28;5(2):59
    Gene markers of cellular aging in human multipotent stromal cells in culture.
    Bellayr IH, Catalano JG, Lababidi S, Yang AX, Lo Surdo JL, Bauer SR, Puri RK
  16. Science 2014 Mar 14;343(6176):1264-6
    Dlk1 promotes a fast motor neuron biophysical signature required for peak force execution.
    Muller D1, Cherukuri P, Henningfeld K, Poh CH, Wittler L, Grote P, Schlüter O, Schmidt J, Laborda J, Bauer SR, Brownstone RM, Marquardt T
  17. Cell Stem Cell 2014 Feb 6;14(2):141-5
    MSC-based product characterization for clinical trials: an FDA perspective.
    Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR
  18. J Biol Chem 2014 Feb 7;289(6):3811-24
    A missense mutation in Rev7 disrupts formation of Polζ, impairing mouse development and repair of genotoxic agent-induced DNA lesions.
    Khalaj M, Abbasi A, Yamanishi H, Akiyama K, Wakitani S, Kikuchi S, Hirose M, Yuzuriha M, Magari M, Degheidy HA, Abe K, Ogura A, Hashimoto H, Kunieda T
  19. Cytotherapy 2013 Dec;15(12):1527-40
    Automated microscopy as a quantitative method to measure differences in adipogenic differentiation in preparations of human mesenchymal stromal cells.
    Lo Surdo JL, Millis BA, Bauer SR
  20. Stem Cell Res Ther 2013;4(5):128
    Assessment of immunosuppressive activity of human mesenchymal stem cells using murine antigen specific CD4 and CD8 T cells in vitro.
    Nazarov C, Lo Surdo J, Bauer SR, Wei CH
  21. Cytometry B Clin Cytom 2013 Jul;84(4):237-47
    Bcl-2 level as a biomarker for 13q14 deletion in CLL.
    Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE
  22. Nanomedicine 2013 Jul;9(5):594-9
    Continuing to strengthen FDA's science approach to emerging technologies.
    Anatol R, Bauer S, Epstein S, Filice R, Lauritsen K, Lee MH, Mansfield E, McMurry-Heath M, Milone J, Pena C, Pollack S, Zineh I
  23. Stem Cell Res 2013 Jun 2;11(2):793-805
    Global proteomic signature of undifferentiated human bone marrow stromal cells: evidence for donor-to-donor proteome heterogeneity.
    Mindaye ST, Ra M, Lo Surdo JL, Bauer SR, Alterman MA
  24. Haematologica 2013 Feb;98(2):163-171
    Dlk1 is a negative regulator of emerging hematopoietic stem and progenitor cells.
    Mirshekar-Syahkal B, Haak E, Kimber GM, van Leusden K, Harvey K, O' Rourke J, Laborda J, Bauer SR, de Bruijn MF, Ferguson-Smith AC, Dzierzak E, Ottersbach K
  25. J Proteomics 2013 Jan 14;78:1-14
    Improved proteomic profiling of the cell surface of culture-expanded human bone marrow multipotent stromal cells.
    Mindaye ST, Ra M, Losurdo J, Bauer SR, Alterman MA
  26. Tissue Eng Part C Methods 2012 Nov;18(11):877-89
    Quantitative approaches to detect donor and passage differences in adipogenic potential and clonogenicity in human bone marrow-derived multipotent stromal cells.
    Lo Surdo JL, Bauer SR
  27. Nature 2011 Jul 20;475(7356):381-5
    Postnatal loss of Dlk1 imprinting in stem cells and niche astrocytes regulates neurogenesis.
    Ferron SR, Charalambous M, Radford E, McEwen K, Wildner H, Hind E, Morante-Redolat JM, Laborda J, Guillemot F, Bauer SR, Farinas I, Ferguson-Smith AC
  28. J Autoimmun 2009 Feb;32(1):14-23
    Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice.
    Scaglione BJ, Salerno E, Gala K, Pan M, Langer JA, Mostowski HS, Bauer S, Marti G, Li Y, Tsiagbe VK, Raveche ES
  29. Stem Cells Dev 2008 Jun;17(3):495-507
    Dlk1 Influences Differentiation and Function of B Lymphocytes.
    Raghunandan R, Ruiz-Hidalgo M, Jia Y, Ettinger R, Rudikoff E, Riggins P, Farnsworth R, Tesfaye A, Laborda J, Bauer SR
  30. Medicine 2008 Mar;87(2):70-86
    Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity.
    Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group
  31. Br J Haematol 2007 Dec;139(5):630-4
    Chronic lymphocytic leukaemia genetics overview.
    Caporaso N, Goldin L, Plass C, Calin G, Marti G, Bauer S, Raveche E, McMaster ML, Ng D, Landgren O, Slager S
  32. J Virol 2007 Jan;81(1):261-71
    Identification of linear heparin binding peptides derived from the human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.
    Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA
  33. Stem Cells 2006 Dec;24(12):2611-7
    Transforming growth factor-beta1 sensitivity is altered in Abl-Myc- and Raf-Myc-induced mouse pre-B-cell tumors.
    Letterio J, Rudikoff E, Voong N, Bauer SR
  34. BMC Genomics 2005 Nov 2;6:150
    Proposed methods for testing and selecting the ERCC external RNA controls.
    External RNA Controls Consortium
  35. Nat Methods 2005 Oct;2(10):731-4
    The External RNA Controls Consortium: a progress report.
    Baker SC, Bauer SR, Beyer RP, Brenton JD, Bromley B, Burrill J, Causton H, Conley MP, Elespuru R, Fero M, Foy C, Fuscoe J, Gao X, Gerhold DL, Gilles P, Goodsaid F, Guo X, Hackett J, Hockett RD, Ikonomi P, Irizarry RA, Kawasaki ES, Kaysser-Kranich T, Kerr K, Kiser G, Koch WH, Lee KY, Liu C, Liu ZL, Lucas A, Manohar CF, Miyada G, Modrusan Z, Parkes H, Puri RK, Reid L, Ryder TB, Salit M, Samaha RR, Scherf U, Sendera TJ, Setterquist RA, Shi L, Shippy R, Soriano JV, Wagar EA, Warrington JA, Williams M, Wilmer F, Wilson M, Wolber PK, Wu X, Zadro R; External RNA Controls Consortium

 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 03/27/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English